Clinical Trial Detail

NCT ID NCT04203160
Title Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors University of Michigan Rogel Cancer Center
Indications

biliary tract cancer

intrahepatic cholangiocarcinoma

extrahepatic bile duct carcinoma

distal biliary tract carcinoma

gallbladder carcinoma

Therapies

Cisplatin + Gemcitabine

Cisplatin + CPI-613 + Gemcitabine

Age Groups: senior adult

No variant requirements are available.